Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # Audion Therapeutics Hearing Loss Drug Discovery ## Sitemaps - [XML Sitemap](https://audiontherapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications](https://audiontherapeutics.com/uncategorized/audion-therapeutics-and-the-regain-consortium-announce-publication-in-nature-communications/) - Audion Therapeutics BV announced today, together with the REGAIN consortium the publication of the results from a Phase I/IIa trial of an intratympanically administered gamma-secretase inhibitor (LY3056480) as a drug treatment for acquired sensorineural hearing loss (ISRCTN number 59733689). - [Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss](https://audiontherapeutics.com/uncategorized/audion-therapeutics-and-regain-consortium-announce-positive-phase-i-results-in-patients-with-sensorineural-hearing-loss/) - The REGAIN consortium, led by Audion Therapeutics BV, a company dedicated to the development of therapeutics for hearing loss, today reports positive results from its Phase I multiple ascending dose, open-label safety study of the Notch Inhibitor LY3056480 in 15 patients with mild to moderate sensorineural hearing loss (SNHL)... - [Audion Therapeutics Raises Funds to Advance the Development of Hearing Loss Treatment](https://audiontherapeutics.com/uncategorized/audion-therapeutics-raises-funds-to-advance-the-development-of-hearing-loss-treatment/) - Audion Therapeutics announced today that it has received a 2.5 million Euro Series B investment from INKEF Capital, a Netherlands based venture capital firm. In addition, Audion announced that, together with a strong international consortium of development partners, it was awarded a 5.8 million Euro grant through the Horizon 2020 program... - [Audion Announces Investment and Licensing Deal With Lilly To Develop Hearing Loss Treatments](https://audiontherapeutics.com/uncategorized/audion-announces-investment-and-licensing-deal-with-lilly-to-develop-hearing-loss-treatments/) - Audion Therapeutics announced today that it has received a Series A investment from Eli Lilly and Company to enable the company to progress its programs targeting sensorineural hearing loss. As part of the investment, the parties also entered into a licensing agreement that gives Audion the rights to certain Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration... - [Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss](https://audiontherapeutics.com/uncategorized/sanofi-enters-into-research-collaboration-with-biopharmaceutical-company-audion-therapeutics-to-develop-potential-treatments-for-hearing-loss/) - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics (Audion) to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach... ## Pages - [Home](https://audiontherapeutics.com/) - Audion Therapeutics is a clinical-stage company dedicated to the development of therapies to treat Hearing Loss About Audion Hearing Loss Acquired Sensorineural Hearing Loss (SNHL), due to aging, exposure to noise or other environmental factors impacts hundreds of millions of people. According to the recently updated World Health Organization estimates, 1 in 4 people worldwide - [Management Team & Founders](https://audiontherapeutics.com/management-team-founders/) - Management Team & Founders Rolf Jan Rutten CEO Rolf Jan Rutten has extensive experience in the pharmaceutical and biotechnology industry, including business development and product development roles with Akzo Nobel, TNO & Clinquest group, and as co-founder of molecular diagnostics company ThromboDx (sold to Illumina) of Dybly AG, a company targeting inflammatory and fibrotic diseases - [News & Publications](https://audiontherapeutics.com/news-publications/) - News & Publications March 4, 2024 Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications Audion Therapeutics BV announced today, together with the REGAIN consortium the publication of the results from a Phase I/IIa trial of an intratympanically administered gamma-secretase inhibitor (LY3056480) as a drug treatment for acquired sensorineural hearing loss (ISRCTN number - [Contact - old](https://audiontherapeutics.com/contact-old/) - Contact General Information, Press & Job Requests If you are a media representative or a medical professional and would like to learn more about the Audion programs, you can use the form on this page to contact us. Partnering with Audion and opportunities to invest We are keen to explore opportunities to partner and collaborate - [Development](https://audiontherapeutics.com/development/) - Development Advanced Development Audion’s lead program has undergone a thorough and extensive preclinical characterization in multiple model systems prior to initiation of the clinical studies. These studies include effects of the drug on damaged inner ear tissue, inner ear PK studies to determine drug exposure using different formulations and formal ototoxicity studies to exclude toxic - [Contact](https://audiontherapeutics.com/contact/) - Contact General Information, Press & Job Requests If you are a media representative or a medical professional and would like to learn more about the Audion programs, you can contact us by email: info@audiontherapeutics.com Partnering with Audion and opportunities to invest We are keen to explore opportunities to partner and collaborate with companies and investors - [Privacy Policy](https://audiontherapeutics.com/privacy-policy/) - Privacy Policy To make you feel comfortable while visiting our website, we would like to inform you about the handling of your data. The following description of our privacy policy is intended to inform you about how we collect, use and pass on your personal data. The responsible company for this website is Citryll BV. - [Investors](https://audiontherapeutics.com/investors/) - Investors Audion is supported by investors that share our motivation to advance treatments for people with hearing loss. - [Our Science](https://audiontherapeutics.com/our-science/) - Our Science Audion’s lead program, a small molecule gamma secretase inhibitor AUD1001, is in clinical development for acquired hearing loss. Pioneering Science Sensorineural hearing loss represents 90% of all hearing loss and is due to damage to the structures of the inner ear and/or the auditory nerve. It is most frequently characterized by dysfunction or - [Hearing Loss](https://audiontherapeutics.com/hearing-loss/) - Hearing Loss Hearing loss affects hundreds of millions people worldwide. The World Health Organization estimates that 500 million people worldwide have a mild to moderate to severe or greater hearing loss. While the prevalence of moderate hearing loss (above 40dB) in the Western population over 70 years old exceeds 27%, the incidence is rising rapidly - [About Audion](https://audiontherapeutics.com/about-audion/) - About Audion Audion Therapeutics is a clinical-stage company dedicated to the development of therapies to treat Hearing Loss. Our lead program is aimed at regenerating cells and neuronal connections that are lost in patients with acquired Sensorineural Hearing Loss (SNHL), which is the most prevalent form of Hearing Loss. The program is based on scientific - [Privacybeleid](https://audiontherapeutics.com/privacybeleid/) - Wie zijn we Voorgestelde tekst: Ons site-adres is: https://audiontherapeutics.com. Reacties Voorgestelde tekst: Als bezoekers reacties achterlaten op de site, verzamelen we de gegevens getoond in het reactieformulier, het IP-adres van de bezoeker en de browser user agent om te helpen spam te detecteren. Een geanonimiseerde string, gemaakt op basis van je e-mailadres (dit wordt ook ## Categories - [Uncategorized](https://audiontherapeutics.com/blog/uncategorized/)